CytomX Therapeutics, Inc. — Q2 2017 Form 10-Q
Business context and reporting period. Unaudited results for the quarter and six months ended June 30, 2017, compared with the same periods in 2016. CytomX is a clinical-stage oncology biopharmaceutical company developing Probody antibody therapeutics. Its lead candidates CX-072 and CX-2009 were in Phase 1/2 trials; the company had no approved products or product-sales revenue.
Financial performance and liquidity
Amounts are in millions of dollars except per-share data. The filing does not present gross profit or gross margin.
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Total revenue | $8.8 | $3.1 | $20.4 | $5.3 |
| Research and development | $28.1 | $12.7 | $42.7 | $26.1 |
| General and administrative | $6.0 | $4.6 | $11.7 | $9.7 |
| Loss from operations | $(25.4) | $(14.3) | $(34.0) | $(30.4) |
| Net loss | $(25.2) | $(14.2) | $(33.5) | $(30.2) |
| Basic and diluted loss per share | $(0.69) | $(0.39) | $(0.91) | $(0.84) |
- Cash and liquidity: At June 30, cash and cash equivalents were $272.9 million and short-term investments were $63.1 million, totaling $335.9 million, versus $181.9 million at December 31, 2016. Current assets were $340.7 million and current liabilities were $60.6 million.
- Cash flow: Six-month operating cash flow was $154.1 million, compared with $10.2 million in 2016. The increase primarily reflected a $200 million BMS upfront payment recorded as deferred revenue, rather than operating profitability. Investing activities provided $12.5 million; financing activities provided $1.6 million. Cash and cash equivalents increased $168.2 million.
- Balance sheet: Total liabilities were $299.6 million, including $283.8 million of deferred revenue. The filing reports no borrowings on the balance sheet. Stockholders’ equity was $52.2 million, and accumulated deficit was $209.8 million.
- Commitments: Operating lease payments totaled $44.9 million, with the facility lease extending to 2026. No material legal proceedings were reported.
Material changes versus the prior comparable period
- Q2 revenue rose $5.7 million year over year; six-month revenue rose $15.1 million. The increases chiefly reflected recognition of collaboration payments, including BMS and AbbVie revenue, and a $6.5 million ImmunoGen license-related payment recognized in the six-month period.
- Operating expenses increased substantially, especially R&D, as CX-072 and CX-2009 advanced into clinical trials. R&D also included a one-time $10 million payment to the University of California, Santa Barbara, triggered by the BMS upfront payment. G&A increases included higher personnel, facility and severance costs.
- Net loss widened to $25.2 million in Q2 from $14.2 million; the six-month net loss increased to $33.5 million from $30.2 million.
- Cash and investments increased by $154.0 million from year-end, principally due to the BMS amendment’s $200 million upfront payment, partly offset by spending and revenue recognition.
Outlook, commentary and key risks
- Management expected existing capital resources to fund operations into 2020 under its current operating plan; the notes also state resources were expected to cover at least 12 months from issuance of the financial statements. Management cautioned that spending may need to be reduced if expected operating results are not achieved and that additional funding will be needed in the future.
- Management expected R&D spending to rise as candidates progress through clinical development. CX-072’s first patient was treated in January 2017 and CX-2009’s in June 2017. An IND filing for the AbbVie-partnered CD71 candidate CX-2029 was anticipated in 2018; BMS anticipated initiating clinical trials for its CTLA-4 candidate by early 2018.
- On July 19, 2017, CytomX achieved an AbbVie CD71 development milestone that triggered a $15 million payment, expected to be recognized as revenue in Q3 2017.
- Principal risks include clinical and regulatory failure or delay, uncertain safety and efficacy of a novel platform, dependence on collaborators and third-party manufacturers, competition, intellectual-property challenges, and the possibility that future financing may be unavailable or dilutive. Collaboration revenue and cash receipts may fluctuate with milestones and partner decisions.
- The company adopted ASU 2016-09 without material financial-statement impact. It planned to adopt the new revenue-recognition standard on January 1, 2018 using the modified retrospective approach; the impact remained under evaluation. Management concluded disclosure controls were effective as of June 30, 2017.
Important facts for investors to verify
- Whether clinical-trial progress and safety data for CX-072 and CX-2009 support the development plans and timelines described.
- How much of the reported revenue and operating cash flow reflects upfront collaboration funding or other nonrecurring items, and the timing of remaining deferred revenue recognition.
- Whether collaboration partners meet development milestones, continue programs and generate the milestone or royalty payments CytomX may be eligible to receive.
- Whether the stated runway into 2020 remains achievable given clinical costs, operating plans and potential financing needs.
- The effects of the new revenue-recognition standard and any future changes in collaboration economics, lease obligations or share dilution.